Gyre Therapeutics (GYRE) Change in Accured Expenses (2010 - 2026)

Gyre Therapeutics (GYRE) has 17 years of Change in Accured Expenses data on file, last reported at $683000.0 in Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at $683000.0, down 84.62% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.8 million (down 157.26% YoY), and the FY2025 annual result was $946000.0, up 163.19% from the prior year.
• Change in Accured Expenses slipped to $683000.0 in Q1 2026 per GYRE's latest filing, from $2.4 million in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $6.2 million in Q4 2022 and troughed at -$4.7 million in Q2 2022.
• A 5-year average of $205411.8 and a median of $683000.0 in 2026 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2022 and 2025: Change in Accured Expenses surged 3441.94% in 2022, then tumbled 3275.71% in 2025.
• A 5-year view of Change in Accured Expenses shows it stood at $6.2 million in 2022, then plunged by 76.06% to $1.5 million in 2023, then surged by 39.95% to $2.1 million in 2024, then advanced by 13.98% to $2.4 million in 2025, then slumped by 71.3% to $683000.0 in 2026.
• Business Quant data shows GYRE's Change in Accured Expenses at $683000.0 in Q1 2026, $2.4 million in Q4 2025, and -$3.5 million in Q3 2025.